Development of monoclonal antibody therapy for treating wounds

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1000673

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chronic wounds, diabetic ulcers, injuries in response to trauma, burns and scalds form a medical need which will only expand as the population ages and the diabetic epidemic grows. In our studies, we have shown that Flightless I (Flii), an actin-remodelling protein, is a negative regulator of wound healing. We are developing monoclonal antibodies as a new therapy for reducing Flii levels in wounds which leads to improved wound repair outcomes.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2013

Funding Scheme: NHMRC Development Grants

Funding Amount: $573,354.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Dermatology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody therapy | cytoskeleton | injury | scarring | wound healing | wound repair

Related Links